IE66332B1
(en)
*
|
1986-11-03 |
1995-12-27 |
Novo Nordisk As |
Piperidine compounds and their preparation and use
|
DK231088D0
(da)
*
|
1988-04-28 |
1988-04-28 |
Ferrosan As |
Piperidinforbindelser, deres fremstilling og anvendelse
|
DK58291D0
(da)
*
|
1991-04-02 |
1991-04-02 |
Novo Nordisk As |
Krystalinsk stof og dets fremstilling
|
GB9209687D0
(en)
*
|
1992-05-06 |
1992-06-17 |
Smithkline Beecham Plc |
Novel process
|
US5258517A
(en)
*
|
1992-08-06 |
1993-11-02 |
Sepracor, Inc. |
Method of preparing optically pure precursors of paroxetine
|
US5276042A
(en)
*
|
1993-04-16 |
1994-01-04 |
Crenshaw Roger T |
Treatment of premature ejaculation
|
EP0639568A1
(en)
*
|
1993-08-19 |
1995-02-22 |
Novo Nordisk A/S |
Piperidine compounds, their preparation and use in the treatment of neurodegenerative disorders
|
US20020086053A1
(en)
*
|
1993-12-15 |
2002-07-04 |
Smithkline Beecham Plc |
Formulations, tablets of paroxetine and process to prepare them
|
GB9325644D0
(en)
*
|
1993-12-15 |
1994-02-16 |
Smithkline Beecham Plc |
Novel formulation
|
ES2102295B1
(es)
*
|
1994-03-18 |
1998-04-01 |
Ferrer Int |
Nuevos compuestos derivados de la n-benzoilmetil-piperidina.
|
SK283608B6
(sk)
*
|
1995-02-06 |
2003-10-07 |
Smithkline Beecham Plc |
Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
|
ES2149726B1
(es)
*
|
1995-02-06 |
2001-06-16 |
Smithkline Beecham Plc |
Nuevos compuestos de paroxetina.
|
GB9502297D0
(en)
|
1995-02-06 |
1995-03-29 |
Smithkline Beecham Plc |
Novel compound
|
GB2297550B
(en)
*
|
1995-02-06 |
1997-04-09 |
Smithkline Beecham Plc |
Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
|
US5856493A
(en)
*
|
1995-02-06 |
1999-01-05 |
Smithkline Beecham Corporation |
Process for making novel form of paroxeting hydrochloride anhydrate
|
US6548084B2
(en)
*
|
1995-07-20 |
2003-04-15 |
Smithkline Beecham Plc |
Controlled release compositions
|
GB9605828D0
(en)
*
|
1996-03-20 |
1996-05-22 |
Smithkline Beecham Plc |
Treatment method
|
CA2206592A1
(en)
*
|
1996-05-30 |
1997-11-30 |
Shu-Zhong Wang |
Method of producing amorphous paroxetine hydrochloride
|
JP3882224B2
(ja)
*
|
1996-05-31 |
2007-02-14 |
旭硝子株式会社 |
パロキセチンの製造方法
|
US5965555A
(en)
*
|
1996-06-07 |
1999-10-12 |
Hoechst Aktiengesellschaft |
Xanthine compounds having terminally animated alkynol side chains
|
EP1384720A1
(en)
*
|
1996-06-13 |
2004-01-28 |
SUMIKA FINE CHEMICALS Co., Ltd. |
Process for drying paroxetine hydrochloride
|
HU221921B1
(hu)
*
|
1996-07-08 |
2003-02-28 |
Richter Gedeon Vegyészeti Gyár Rt. |
N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
|
WO1998002556A2
(en)
*
|
1996-07-15 |
1998-01-22 |
Smithkline Beecham Plc |
Screening for and use of an esterase for a stereospecific resolution
|
US5672612A
(en)
*
|
1996-09-09 |
1997-09-30 |
Pentech Pharmaceuticals, Inc. |
Amorphous paroxetine composition
|
US6638948B1
(en)
|
1996-09-09 |
2003-10-28 |
Pentech Pharmaceuticals, Inc. |
Amorphous paroxetine composition
|
CA2193939C
(en)
*
|
1996-12-24 |
2002-02-12 |
K.S. Keshava Murthy |
Useful form of anhydrous paroxetine hydrochloride
|
EP1078925A1
(en)
*
|
1997-06-10 |
2001-02-28 |
Synthon B.V. |
4-Phenylpiperidine compounds
|
US5955475A
(en)
*
|
1997-06-30 |
1999-09-21 |
Endo Pharmaceuticals Inc. |
Process for manufacturing paroxetine solid dispersions
|
GB9726907D0
(en)
*
|
1997-12-19 |
1998-02-18 |
Smithkline Beecham Plc |
Novel compounds
|
KR20010040711A
(ko)
*
|
1998-02-06 |
2001-05-15 |
피터 기딩스 |
파록세틴의 염
|
AP2000001907A0
(en)
*
|
1998-03-16 |
2000-09-30 |
Smithkline Beecham Plc |
Crystalline form of paroxetine.
|
US6699882B2
(en)
|
1998-03-24 |
2004-03-02 |
Smithkline Beecham P.L.C. |
Paroxetine compositions
|
AU2003200534B2
(en)
*
|
1998-03-24 |
2004-12-02 |
Smithkline Beecham Plc |
Paroxetine compositions
|
GB9806312D0
(en)
*
|
1998-03-24 |
1998-05-20 |
Smithkline Beecham Plc |
Novel formulations
|
GB9808894D0
(en)
*
|
1998-04-25 |
1998-06-24 |
Smithkline Beecham Plc |
Novel compound
|
GB9808896D0
(en)
*
|
1998-04-25 |
1998-06-24 |
Smithkline Beecham Plc |
Novel compound
|
GB9812941D0
(en)
*
|
1998-06-16 |
1998-08-12 |
Smithkline Beecham Plc |
Method of treatment
|
US6300343B1
(en)
|
1998-06-16 |
2001-10-09 |
Smithkline Beecham Corporation |
Method of treatment
|
GB9814316D0
(en)
*
|
1998-07-02 |
1998-09-02 |
Smithkline Beecham Plc |
Novel compounds
|
CH689805A8
(fr)
*
|
1998-07-02 |
2000-02-29 |
Smithkline Beecham Plc |
Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
|
ES2138937B1
(es)
|
1998-07-07 |
2000-10-01 |
Medichem Sa |
Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.
|
PT1100796E
(pt)
*
|
1998-08-07 |
2003-09-30 |
Smithkline Beecham Plc |
Processo para a preparacao de um cloridrato de paroxetina na forma anidra nao cristalina
|
EP1102764A1
(en)
*
|
1998-08-08 |
2001-05-30 |
Smithkline Beecham Plc |
Paroxetine salts
|
GB9824298D0
(en)
*
|
1998-11-05 |
1998-12-30 |
Smithkline Beecham Plc |
Novel process
|
GB9826176D0
(en)
*
|
1998-11-28 |
1999-01-20 |
Smithkline Beecham Plc |
Novel process
|
GB9826175D0
(en)
*
|
1998-11-28 |
1999-01-20 |
Smithkline Beecham Plc |
Novel process
|
GB9826178D0
(en)
*
|
1998-11-30 |
1999-01-20 |
Smithkline Beecham Plc |
Novel process
|
GB9826180D0
(en)
*
|
1998-11-30 |
1999-01-20 |
Smithkline Beecham Plc |
Novel process
|
GB9826171D0
(en)
*
|
1998-11-30 |
1999-01-20 |
Smithkline Beecham Plc |
Novel compounds
|
GB9826242D0
(en)
*
|
1998-11-30 |
1999-01-20 |
Smithkline Beecham Plc |
Novel process
|
WO2000032594A1
(en)
*
|
1998-11-30 |
2000-06-08 |
Smithkline Beecham Plc |
Mixed paroxetine propan-2-ol solvates
|
GB9827387D0
(en)
*
|
1998-12-11 |
1999-02-03 |
Smithkline Beecham Plc |
Novel process
|
GB9828780D0
(en)
*
|
1998-12-29 |
1999-02-17 |
Smithkline Beecham Plc |
Novel process
|
GB9828779D0
(en)
*
|
1998-12-29 |
1999-02-17 |
Smithkline Beecham Plc |
Novel process
|
GB9828781D0
(en)
*
|
1998-12-29 |
1999-02-17 |
Smithkline Beecham Plc |
Novel process
|
GB9828767D0
(en)
*
|
1998-12-29 |
1999-02-17 |
Smithkline Beecham Plc |
Novel process
|
EP1161241B1
(de)
*
|
1999-03-12 |
2005-12-07 |
Aesica Pharmaceuticals Ltd. |
Stabile pharmazeutische anwendungsform für paroxetin-anhydrat
|
FR2791345B1
(fr)
*
|
1999-03-26 |
2001-05-04 |
Adir |
Nouveaux derives du benzo[3,4]cyclobuta[1,2-c]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
US6245782B1
(en)
|
1999-05-17 |
2001-06-12 |
Heartdrug Research L.L.C. |
Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
|
GB9914583D0
(en)
*
|
1999-06-22 |
1999-08-25 |
Smithkline Beecham Plc |
Novel process
|
GB9914585D0
(en)
*
|
1999-06-22 |
1999-08-25 |
Smithkline Beecham Plc |
Novel process
|
ATE248165T1
(de)
|
1999-07-01 |
2003-09-15 |
Italfarmaco Spa |
Komplexe von paroxetin mit cyclodextrin oder cyclodextrin derivaten
|
GB9916187D0
(en)
*
|
1999-07-09 |
1999-09-08 |
Smithkline Beecham Plc |
Novel process
|
GB9919052D0
(en)
*
|
1999-08-12 |
1999-10-13 |
Smithkline Beecham Plc |
Novel compound composition and process
|
GB9923446D0
(en)
*
|
1999-10-04 |
1999-12-08 |
Smithkline Beecham Plc |
Novel process
|
US6503927B1
(en)
|
1999-10-28 |
2003-01-07 |
Pentech Pharmaceuticals, Inc. |
Amorphous paroxetine composition
|
GB0003232D0
(en)
*
|
2000-02-11 |
2000-04-05 |
Smithkline Beecham Plc |
Novel composition
|
HU226912B1
(en)
*
|
2000-04-07 |
2010-03-01 |
Richter Gedeon Nyrt |
New paroxetin salt and medicament containing it
|
AU5702201A
(en)
*
|
2000-04-13 |
2001-10-30 |
Mayo Foundation |
Abeta<sub>42</sub> lowering agents
|
US6660298B1
(en)
*
|
2000-07-27 |
2003-12-09 |
Pentech Pharmaceuticals, Inc. |
Paroxetine tablets and capsules
|
US20030109577A1
(en)
*
|
2000-10-27 |
2003-06-12 |
Ken Liljegren |
Pharmaceutical composition containing citalopram
|
DE20100529U1
(de)
*
|
2001-01-11 |
2001-05-10 |
Synthon Bv |
Pharmazeutische Tablette umfassend Paroxetinmesylat
|
US6610326B2
(en)
|
2001-02-16 |
2003-08-26 |
Andrx Corporation |
Divalproex sodium tablets
|
US6720003B2
(en)
*
|
2001-02-16 |
2004-04-13 |
Andrx Corporation |
Serotonin reuptake inhibitor formulations
|
NL1017421C2
(nl)
|
2001-02-21 |
2002-01-15 |
Synthon Bv |
Werkwijze voor het vervaardigen van paroxetine.
|
US6645946B1
(en)
|
2001-03-27 |
2003-11-11 |
Pro-Pharmaceuticals, Inc. |
Delivery of a therapeutic agent in a formulation for reduced toxicity
|
CA2457382A1
(en)
*
|
2001-06-13 |
2002-12-19 |
Teva Pharmaceutical Industries Ltd. |
Process for the preparation of paroxetine substantially free of alkoxy impurities
|
IL159280A0
(en)
*
|
2001-06-14 |
2004-06-01 |
Teva Pharma |
A process for preparing paroxetine hcl which limits formation of pink colored compounds
|
EA006213B1
(ru)
*
|
2001-07-31 |
2005-10-27 |
Х. Лундбекк А/С |
Кристаллическая композиция, содержащая эсциталопрам
|
CA2456233A1
(en)
*
|
2001-08-02 |
2003-03-13 |
Spurcourt Limited |
Paroxetine isethionate salt, process of preparation and use in the treatment of depression
|
JP2005501066A
(ja)
*
|
2001-08-09 |
2005-01-13 |
スミスクライン ビーチャム パブリック リミテッド カンパニー |
パロキセチンおよび医薬上許容されるグリチルリチン酸塩を含む組成物
|
PT1440067E
(pt)
*
|
2001-10-22 |
2005-02-28 |
Synthon Bv |
Derivados n-formilo de paroxetina
|
AU2002360775B9
(en)
*
|
2001-12-28 |
2008-07-24 |
Teva Pharmaceutical Industries Ltd. |
A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
|
IL163666A0
(en)
|
2002-02-22 |
2005-12-18 |
New River Pharmaceuticals Inc |
Active agent delivery systems and methods for protecting and administering active agents
|
AU2002259114A1
(en)
*
|
2002-02-22 |
2003-09-09 |
Teva Pharmaceutical Industries Ltd. |
Preparation of paroxetine involving novel intermediates
|
US6956121B2
(en)
|
2002-03-01 |
2005-10-18 |
Teva Pharmaceutical Industries Ltd. |
Preparation of paroxetine involving novel intermediates
|
UA77536C2
(en)
*
|
2002-07-03 |
2006-12-15 |
Lundbeck & Co As H |
Secondary aminoaniline piperidines as mch1 antagonists and their use
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
JP4394004B2
(ja)
*
|
2002-09-19 |
2010-01-06 |
住友化学株式会社 |
結晶析出方法
|
US20060041138A1
(en)
*
|
2002-09-19 |
2006-02-23 |
Shigeya Yamazaki |
Process for producing paroxetine hydrochloride hydrate
|
US20040220153A1
(en)
*
|
2002-09-24 |
2004-11-04 |
Jost-Price Edward Roydon |
Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
|
WO2004071431A2
(en)
*
|
2003-02-05 |
2004-08-26 |
Myriad Genetics, Inc. |
Method and composition for treating neurodegenerative disorders
|
DE602004004453T2
(de)
*
|
2003-03-12 |
2007-11-08 |
Teva Pharmaceutical Industries Ltd. |
Stabile pharmazeutische zusammensetzungen mit desloratadin
|
US20060135547A1
(en)
*
|
2003-03-12 |
2006-06-22 |
Toth Zoltan G |
Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
|
AU2004311577A1
(en)
*
|
2003-07-11 |
2005-07-21 |
Myriad Genetics, Inc. |
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
|
EP1691811B1
(en)
|
2003-12-11 |
2014-07-23 |
Sunovion Pharmaceuticals Inc. |
Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
|
US20050154020A1
(en)
*
|
2004-01-14 |
2005-07-14 |
Synaptic Pharmaceutical Corporation |
4-Aryl piperidines
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
WO2006001877A2
(en)
*
|
2004-04-13 |
2006-01-05 |
Myriad Genetics, Inc. |
Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
|
EP1737473A4
(en)
*
|
2004-04-19 |
2009-08-26 |
Noven Therapeutics Llc |
COMBINATIONS OF LITHIUM AND USES THEREOF
|
US20050252144A1
(en)
*
|
2004-04-29 |
2005-11-17 |
Macdonald Robert A |
Veneers for walls, retaining walls and the like
|
US20050266082A1
(en)
*
|
2004-05-26 |
2005-12-01 |
Patel Satishkumar A |
Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
BRPI0514303A
(pt)
*
|
2004-08-11 |
2008-06-10 |
Myriad Genetics Inc |
composição farmacêutica e método para tratar distúrbios neurodegenerativos
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
EP1778183B1
(en)
*
|
2004-08-18 |
2018-06-27 |
Synthon B.V. |
Liquid paroxetine compositions
|
EP1791531A1
(en)
*
|
2004-08-20 |
2007-06-06 |
Alpharma, Inc. |
Paroxetine formulations
|
KR100672184B1
(ko)
*
|
2004-09-21 |
2007-01-19 |
주식회사종근당 |
파록세틴의 콜린산 또는 콜린산 유도체 염
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
DE102004056398A1
(de)
*
|
2004-11-23 |
2006-05-24 |
Bayer Materialscience Ag |
Hydrolysestabile, hydrophobe, lösemittelfreie Polyole
|
US20060216345A1
(en)
*
|
2005-03-24 |
2006-09-28 |
Sun Pharmaceutical Industries Limited |
Oral pharmaceutical composition including paroxetine
|
ATE407933T1
(de)
*
|
2005-05-26 |
2008-09-15 |
Apotecnia S A |
Verfahren zur herstellung von paroxetin hydrochlorid hemihydrat
|
US20070015832A1
(en)
*
|
2005-07-14 |
2007-01-18 |
Myriad Genetics, Incorporated |
Methods of treating overactive bladder and urinary incontinence
|
CA2615063A1
(en)
*
|
2005-07-22 |
2007-02-01 |
Myriad Genetics, Inc. |
High drug load formulations and dosage forms
|
DE102005035891A1
(de)
*
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
KR100591142B1
(ko)
*
|
2005-11-04 |
2006-06-20 |
지엘팜텍 주식회사 |
파록세틴을 활성물질로 함유하는 장용성 서방형 정제
|
WO2007054978A2
(en)
*
|
2005-11-10 |
2007-05-18 |
Jubilant Organosys Limited |
Process for preparing paroxetine hydrochloride hemihydrate
|
AU2006315684A1
(en)
*
|
2005-11-14 |
2007-05-24 |
Auspex Pharmaceuticals, Inc. |
Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
|
NO347644B1
(no)
|
2006-05-04 |
2024-02-12 |
Boehringer Ingelheim Int |
Polymorfer
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
US20080033045A1
(en)
*
|
2006-07-07 |
2008-02-07 |
Myriad Genetics, Incorporated |
Treatment of psychiatric disorders
|
WO2008012623A1
(en)
*
|
2006-07-25 |
2008-01-31 |
Pfizer Products Inc. |
Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
|
US20080033050A1
(en)
|
2006-08-04 |
2008-02-07 |
Richards Patricia Allison Tewe |
Method of treating thermoregulatory disfunction with paroxetine
|
DK2118074T3
(en)
|
2007-02-01 |
2014-03-10 |
Resverlogix Corp |
Compounds for the prevention and treatment of cardiovascular diseases
|
US20080300258A1
(en)
*
|
2007-05-30 |
2008-12-04 |
Souza Fabio Eduardo Silva |
Anhydrous ciprofloxacin hydrochloride
|
US9138430B2
(en)
*
|
2007-12-27 |
2015-09-22 |
Mylan Specialty L.P. |
Formulation and method for the release of paroxetine in the large intestine
|
AR071175A1
(es)
|
2008-04-03 |
2010-06-02 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
|
DE102009030506A1
(de)
*
|
2008-06-30 |
2009-12-31 |
Borgwarner Inc., Auburn Hills |
Reibungsmaterialien
|
KR20200118243A
(ko)
|
2008-08-06 |
2020-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
MX2011002558A
(es)
|
2008-09-10 |
2011-04-26 |
Boehringer Ingelheim Int |
Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
US8865729B2
(en)
|
2008-12-23 |
2014-10-21 |
Boehringer Ingelheim International Gmbh |
Salt forms of a xanthine compound
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
CA2992231C
(en)
|
2009-03-18 |
2022-03-29 |
Resverlogix Corp. |
Phenyl-quinazolin-4(3h)-one and phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one derivatives and compositions thereof useful as anti-inflammatory agents
|
JP2010260826A
(ja)
*
|
2009-05-08 |
2010-11-18 |
Sumitomo Chemical Co Ltd |
パロキセチン塩酸塩半水和物の製造方法
|
AU2010323068B2
(en)
|
2009-11-27 |
2015-09-03 |
Boehringer Ingelheim International Gmbh |
Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
|
WO2011138421A1
(en)
|
2010-05-05 |
2011-11-10 |
Boehringer Ingelheim International Gmbh |
Combination therapy
|
JP5700367B2
(ja)
*
|
2010-05-06 |
2015-04-15 |
高田製薬株式会社 |
パロキセチン含有フイルムコ−テイング経口製剤
|
KR20190050871A
(ko)
|
2010-06-24 |
2019-05-13 |
베링거 인겔하임 인터내셔날 게엠베하 |
당뇨병 요법
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
EP2685966A1
(en)
|
2011-03-17 |
2014-01-22 |
Lupin Limited |
Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
|
GB201108345D0
(en)
*
|
2011-05-18 |
2011-06-29 |
Aesica Pharmaceuticals Ltd |
Process
|
KR101985384B1
(ko)
|
2011-07-15 |
2019-06-03 |
베링거 인겔하임 인터내셔날 게엠베하 |
치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
|
CN102285973B
(zh)
*
|
2011-09-20 |
2013-03-06 |
海南美大制药有限公司 |
一种盐酸帕罗西汀化合物及其制法
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
EP2849755A1
(en)
|
2012-05-14 |
2015-03-25 |
Boehringer Ingelheim International GmbH |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
AU2013204159B2
(en)
*
|
2013-03-15 |
2015-05-07 |
Bionomics Limited |
A Crystalline Form of an Anxiolytic Compound
|
WO2015128453A1
(en)
|
2014-02-28 |
2015-09-03 |
Boehringer Ingelheim International Gmbh |
Medical use of a dpp-4 inhibitor
|
CN104447714A
(zh)
*
|
2014-11-18 |
2015-03-25 |
成都医路康医学技术服务有限公司 |
一种盐酸帕罗西汀的生产工艺
|
US10155000B2
(en)
|
2016-06-10 |
2018-12-18 |
Boehringer Ingelheim International Gmbh |
Medical use of pharmaceutical combination or composition
|